NSE · IN
NATCOPHARM
Charting by TradingView
history source: yahoo-finance-unofficial · SMA 20 (blue) · EMA 20 (orange) · volume below, coloured by the day's direction
Key figures
23% of the way up its 52-week range
Valuation
- Market cap
- ₹16,298 cr
- P/E (TTM)
- 11.49
- P/S (TTM)
- 4.00
- P/B
- 1.77
- EPS (TTM)
- ₹79.25
Profitability
- Gross margin
- 83.1%
- Operating margin
- 30.2%
- Net margin
- 34.8%
- ROE
- 15.4%
Growth & health
- Revenue growth (YoY)
- -39.5%
- EPS growth (YoY)
- -34.1%
- Debt / equity
- 0.08
- Interest coverage
- 41.6
- Dividend yield
- 0.55%
Corporate calendar
NSE announcements- Corporate actionFund Raisingex-date14 Aug 20264d ago
- ResultsFinancial Results/Dividendboard meets to approve results14 Aug 20264d ago
- DividendInterim Dividend - Rs 1.50 Per Shareex-date · record date 20 Aug 202620 Aug 2026in 2d
Quarterly financials
Consolidated · from company filings to NSE| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q1 FY272026-06-30 | ₹735 cr | -44.7% | ₹207 cr | -57.0% | 28.1% |
| Q4 FY262026-03-31 | ₹739 cr | -39.5% | ₹269 cr | -33.7% | 36.4% |
| Q3 FY262025-12-31 | ₹647 cr | — | ₹151 cr | — | 23.4% |
| Q2 FY262025-09-30 | ₹1,363 cr | — | ₹518 cr | — | 38.0% |
| Q1 FY262025-06-30 | ₹1,329 cr | — | ₹480 cr | — | 36.1% |
| Q4 FY252025-03-31 | ₹1,221 cr | — | ₹406 cr | — | 33.3% |
Growth compares each quarter with the same quarter a year earlier, which is the like-for-like comparison for seasonal businesses. Growth is not shown where the year-ago figure was a loss, since the percentage would be misleading.
Cash flow & segments
FY26 · consolidated · annual filingBusiness segments
- Pharmaceuticals₹717 cr(97%)PBIT ₹155 cr · 21.7% margin
- Agro chemicals₹22.6 cr(3%)PBIT −₹0.4 cr · -1.8% margin
Institutional ownership
quarter ended 2026-06-30 · ~2 months old| Holder | Stake | Change vs 2026-03-31 |
|---|---|---|
| Promoter | 49.42% | 0.00 pp |
| DII (domestic institutions) | 5.62% | +0.16 pp |
| FII (foreign institutions) | 16.99% | -0.38 pp |
| Public (non-institutional) | 27.97% | — |
| Govt / other | — | — |
Net institutional change: -0.22 pp (FII + DII combined)
Shareholding patterns are disclosed quarterly by NSE, so this shows ownership as of the quarter end — not current or intraday activity. Per-stock daily FII/DII flow is not publicly published.
Ownership & stake news
- Natco Pharma raises Adcock Ingram stake to 49%, pays ₹1,060 croreBusinessLine · 35d ago
- NATCO Pharma Completes Rs 1,060 Crore Adcock Ingram Stake AcquisitionMedical Dialogues · 35d ago
- NATCO Pharma raises stake in South Africa’s Adcock Ingram to 49%Indian Pharma Post · 34d ago
- Natco Pharma to Raise Stake in South Africa's Adcock Ingram to 49% in Rs 1,069 Crore DealMedical Dialogues · 39d ago
- This Low PE Pharma Stock Approves Rs 1,400 Crore South Africa Expansion; Stake in Adcock Ingram to Rise to 49%Dalal Street Investment Journal · 41d ago
Bulk & block deals
NSE disclosures · last 12 months · 1 active day| Date | Counterparty | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 26 Nov 2025 | GRAVITON RESEARCH CAPITAL LLP | SELL | 11.99 L | ₹904.93 | ₹108.5 cr |
| 26 Nov 2025 | GRAVITON RESEARCH CAPITAL LLP | BUY | 11.99 L | ₹904.19 | ₹108.4 cr |
Bulk deals are trades above 0.5% of listed shares in a day; block deals are single negotiated trades of ₹10 crore or more. A large trade can be disclosed under both rules, and both the buyer and the seller are named, so rows often pair up — that is one transfer, not two.